SILO PHARMA, INC. Income (Loss) from Equity Method Investments
SILO PHARMA, INC. (SILO) reported Income (Loss) from Equity Method Investments of -$3.12 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2024-03-25
- SILO PHARMA, INC. income (loss) from equity method investments for the quarter ending 2023-12-31 was $0.00.
- SILO PHARMA, INC. income (loss) from equity method investments for the quarter ending 2023-09-30 was $0.00.
- SILO PHARMA, INC. income (loss) from equity method investments for the quarter ending 2023-06-30 was -$3.51K.
- SILO PHARMA, INC. income (loss) from equity method investments for the quarter ending 2023-03-31 was $390.00.
- SILO PHARMA, INC. income (loss) from equity method investments for fiscal 2023 was -$3.12K.
- SILO PHARMA, INC. income (loss) from equity method investments for fiscal 2022 was -$331.20K, a 104.97% decline from fiscal 2021.
- SILO PHARMA, INC. income (loss) from equity method investments for fiscal 2021 was $6.66M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 6 month as first filed | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 9 month as first filed | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | -$3.51K derived: sum of 3 quarters · filed 2024-03-25 | -$3.12K 10-K · filed 2024-03-25 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$3.51K derived: sum of 2 quarters · filed 2023-11-13 | -$3.12K 10-Q · filed 2023-11-13 | -$77.94K derived: sum of 4 quarters · filed 2024-03-25 | |||
| 2023-06-30 | -$3.51K 10-Q · filed 2023-08-11 | -$3.12K 10-Q · filed 2023-08-11 | -$77.94K derived: sum of 3 quarters · filed 2024-03-25 | -$113.01K derived: sum of 4 quarters · filed 2024-03-25 | |||
| 2023-03-31 | $390.00 derived: 10-K 12 month − 3 quarters · filed 2024-03-25 | -$74.43K derived: sum of 2 quarters · filed 2024-03-25 | -$109.50K derived: sum of 3 quarters · filed 2024-03-25 | -$169.01K derived: sum of 4 quarters · filed 2024-03-25 | |||
| 2022-12-31 | -$74.82K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$109.89K derived: sum of 2 quarters · filed 2024-03-25 | -$169.41K derived: sum of 3 quarters · filed 2024-03-25 | -$331.20K 10-K · filed 2024-03-25 | -$104.70K 10-K · filed 2023-03-24 | ||
| 2022-09-30 | -$35.07K 10-Q · filed 2023-11-13 | -$94.58K derived: sum of 2 quarters · filed 2023-11-13 | -$256.38K 10-Q · filed 2023-11-13 | -$104.70K 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | -$59.51K 10-Q · filed 2023-08-11 | -$221.31K 10-Q · filed 2023-08-11 | -$104.70K 10-Q · filed 2022-08-01 | ||||
| 2021-12-31 | $5.36K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $6.66M 10-K · filed 2023-03-24 | |||||
| 2021-09-30 | $6.66M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |